MSI-H
Entity.
- Evidence
- 76 documents · 32 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 1 Oct 2026
- Measured
- 9% of mentions say something specific about it; the rest only name it
- As of
- 6 Oct 2026
Where this comes from
- J Immunother Cancer · 2026-10-01 · Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer. (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-01 · Molecular profiling and prognostic significance of gastric cancer subtypes based on extracellular vesicle-related characteristics (opens the source in a new tab)
- Jpn J Clin Oncol · 2026-10-01 · Age- and sex-specific prevalence of deficient mismatch repair protein expression in gastric, colorectal, and endometrial cancers: a center-based study of older Japanes… (opens the source in a new tab)
- Clin Cancer Res · 2026-10-01 · A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer. (opens the source in a new tab)
- Clin Case Rep · 2026-09-09 · A Lynch Syndrome Family With Germline MLH1 c.931A>G Showing Preserved Tumor MMR Immunostaining but MSI-H Status: A Case Report. (opens the source in a new tab)
- Annals of Oncology · 2026-09-06 · Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-… (opens the source in a new tab)
- Front Cell Infect Microbiol · 2026-09-03 · Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therape… (opens the source in a new tab)
- crc-digest · 2026-09-02 · Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC (opens the source in a new tab)
- ESMO Gastrointest Oncol · 2026-09-01 · Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab. (opens the source in a new tab)
- crc-digest · 2026-08-25 · Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer (opens the source in a new tab)
- MSI-H · 2026-08-23 · Immunotherapy (MSI-H) (opens the source in a new tab)
- Clin Colorectal Cancer · 2026-07-31 · Durable Responses to Immunotherapy in dMMR/MSI-H Metastatic Colorectal Cancer Patients With Poor Performance Status. (opens the source in a new tab)
What is claimed about it
- Single source: Reported by one source so far.
- Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer Single source · first reported 1 Oct 2026
- Age- and sex-specific prevalence of deficient mismatch repair protein expression in gastric, colorectal, and endometrial cancers: a center-based study of older Japanese patients. Single source · first reported 1 Oct 2026